In Apotex, Inc. v. UCB, Inc. (Fed. Cir. Aug. 15, 2014) (Reyna (auth), Wallach, Hughes) the panel affirmed the holding of the Southern District of Florida that the ‘556 patent was unenforceable due to inequitable conduct. Honestly, it appears to be a truly egregious case — involving experiments that were never run, false affidavits, and more.
The doctrine still has some fight left.